About Plus Therapeutics, Inc.
https://www.plustherapeutics.comPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
CEO
Marc H. Hedrick
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-05-01 | Reverse | 1:15 |
| 2019-08-06 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:1.45M
Value:$408.29K
ALTIUM CAPITAL MANAGEMENT LP
Shares:918.91K
Value:$259.32K
GEODE CAPITAL MANAGEMENT, LLC
Shares:813.25K
Value:$229.5K
Summary
Showing Top 3 of 27
About Plus Therapeutics, Inc.
https://www.plustherapeutics.comPlus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.4M ▲ | $5.79M ▲ | $-4.42M ▼ | -316.61% ▼ | $-0.04 ▼ | $-4.34M ▼ |
| Q2-2025 | $1.39M ▲ | $2.84M ▼ | $5.15M ▲ | 370.58% ▲ | $0.02 ▲ | $5.27M ▲ |
| Q1-2025 | $1.06M ▼ | $4.41M ▼ | $-17.4M ▼ | -1.64K% ▼ | $-1.19 ▼ | $-13.46M ▼ |
| Q4-2024 | $1.41M ▼ | $5.08M ▲ | $-3.9M ▼ | -276.42% ▼ | $-0.5 ▼ | $-3.61M ▼ |
| Q3-2024 | $1.46M | $5.02M | $-2.87M | -197.39% | $-0.37 | $-2.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $13.29M ▲ | $18.67M ▲ | $13.62M ▲ | $5.05M ▲ |
| Q2-2025 | $6.88M ▼ | $10.35M ▼ | $7.32M ▼ | $3.03M ▲ |
| Q1-2025 | $9.87M ▲ | $12.06M ▲ | $35.7M ▲ | $-23.64M ▼ |
| Q4-2024 | $3.61M ▼ | $6.63M ▼ | $15.58M ▲ | $-8.95M ▼ |
| Q3-2024 | $4.79M | $6.98M | $12.15M | $-5.17M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.42M ▼ | $-2.55M ▲ | $1.3M ▲ | $12.31M ▲ | $11.06M ▲ | $-2.58M ▲ |
| Q2-2025 | $5.15M ▲ | $-5.8M ▲ | $-4.63M ▼ | $2.8M ▼ | $-7.63M ▼ | $-5.8M ▲ |
| Q1-2025 | $-17.4M ▼ | $-6.17M ▼ | $3.56M ▲ | $12.4M ▲ | $9.79M ▲ | $-6.17M ▼ |
| Q4-2024 | $-3.9M ▼ | $-1.21M ▲ | $64K ▲ | $0 | $-1.15M ▲ | $-1.22M ▲ |
| Q3-2024 | $-2.87M | $-3.68M | $-9K | $0 | $-3.69M | $-3.69M |
Revenue by Products
| Product | Q1-2023 | Q3-2023 | Q2-2024 | Q3-2024 |
|---|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2018 | Q4-2018 | Q2-2018 | Q1-2019 |
|---|---|---|---|---|
 Americas | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Asia Pacific | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 EMEA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 JAPAN | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Marc H. Hedrick
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-05-01 | Reverse | 1:15 |
| 2019-08-06 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:1.45M
Value:$408.29K
ALTIUM CAPITAL MANAGEMENT LP
Shares:918.91K
Value:$259.32K
GEODE CAPITAL MANAGEMENT, LLC
Shares:813.25K
Value:$229.5K
Summary
Showing Top 3 of 27